Article: Determination of acetylator phenotype in Caucasians with caffeine

Acetylator status in 595 healthy Caucasian volunteers was determined with caffeine. The test group consisted of 372 males and 223 females, 18 to 78 years of age. 312 volunteers were smokers. Caffeine was taken orally as Coffein Comprette (200 mg caffeine x H2O) and urine was collected for 8 h. The metabolic ratio (MR) of 5-acetylamino-6-formylamino-1-methyluracil (AFMU) to 1-methylxanthine (MX) was determined by HPLC. In total 61.7% of the group had a MR less than 0.48 and were classified as slow acetylators. MR varied from 0.01 to 0.47 in the slow acetylators and from 0.48 to 4.7 in the fast acetylator group. Clear dependence of acetylator type upon age, sex or smoking behaviour was not observed. The present study has confirmed the caffeine test as a feasible tool to determine acetylation capacity.

Citing Articles

Clinical and Molecular Risk Factors of Anti-tubercular Therapy Induced Hepatitis.

Kar P, Karna R, Ruttala R, Arora S, Chakravarty A, Kumar S J Clin Exp Hepatol. 2019; 9(2):200-206.

PMID: 31024202 PMC: 6477131. DOI: 10.1016/j.jceh.2018.06.012.

Host factors in occupational diisocyanate asthma: a Swiss longitudinal study.

Berode M, Jost M, Ruegger M, Savolainen H Int Arch Occup Environ Health. 2005; 78(2):158-63.

PMID: 15714334 DOI: 10.1007/s00420-004-0568-4.

References

1.

Grant D, Tang B, KALOW W . Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther. 1983; 33(3):355-9. DOI: 10.1038/clpt.1983.45. View

2.

Vree T, OREILLY W, Hekster Y, Damsma J, van der Kleijn E . Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man. Clin Pharmacokinet. 1980; 5(3):274-94. DOI: 10.2165/00003088-198005030-00006. View

3.

Grant D, Tang B, KALOW W . Variability in caffeine metabolism. Clin Pharmacol Ther. 1983; 33(5):591-602. DOI: 10.1038/clpt.1983.80. View

4.

Varughese P, Hamilton E, EIDUS L . Mass phenotyping of isoniazid inactivators by automated determination of acetylisoniazid in urine. Clin Chem. 1974; 20(6):639-41. View

5.

Hildebrand M, Seifert W, Reichenberger A . Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol. 1989; 36(3):315-8. DOI: 10.1007/BF00558166. View

6.

HUGHES H, BIEHL J, Jones A, Schmidt L . Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc. 1954; 70(2):266-73. DOI: 10.1164/art.1954.70.2.266. View

7.

Ludden T, McNay Jr J, Shepherd A, Lin M . Clinical pharmacokinetics of hydralazine. Clin Pharmacokinet. 1982; 7(3):185-205. DOI: 10.2165/00003088-198207030-00001. View

8.

Tang B, KADAR D, KALOW W . An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther. 1987; 42(5):509-13. DOI: 10.1038/clpt.1987.189. View

9.

Lima J, Jusko W . Determination of procainamide acetylator status. Clin Pharmacol Ther. 1978; 23(1):25-9. DOI: 10.1002/cpt197823125. View

10.

Reidenberg M, Drayer D, Levy M, Warner H . Polymorphic acetylation procainamide in man. Clin Pharmacol Ther. 1975; 17(6):722-30. DOI: 10.1002/cpt1975176722. View

11.

Grant D, Tang B, KALOW W . A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol. 1984; 17(4):459-64. PMC: 1463406. DOI: 10.1111/j.1365-2125.1984.tb02372.x. View

12.

Weber W, Hein D . N-acetylation pharmacogenetics. Pharmacol Rev. 1985; 37(1):25-79. View

Determination of Acetylator Phenotype in Caucasians with Caffeine